Rocket Pharmaceuticals General Counsel Wilson Martin reported an open-market sale of company stock. On February 18, 2026, he sold 1,376 shares of Common Stock at an average price of $3.338 per share in a transaction classified as an open-market sale.
According to the footnotes, the shares were sold to pay tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). After this sale, Martin beneficially owned 682,000 shares, which include RSUs that convert to common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. General Counsel Wilson Martin sold 12,253 shares of common stock on February 13, 2026 in an open-market transaction at an average price of $3.312 per share. According to the disclosure, the sale was made to pay tax withholding obligations tied to the vesting of restricted stock units (RSUs). After this transaction, Martin directly owned 683,376 shares, and his holdings include RSUs that convert into common stock on a one-for-one basis.
Rocket Pharmaceuticals officer John Militello reported an open-market sale of 3,726 shares of common stock at $3.312 per share. According to the footnotes, the sale was made to cover tax withholding obligations from vested restricted stock units, and Militello now holds 92,176 shares, including RSUs that convert to common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah sold 12,279 shares of common stock at $3.312 per share on February 13, 2026 in an open-market transaction. According to the footnotes, the sale was made to cover tax withholding obligations tied to vesting restricted stock units that convert one-for-one into common shares. After this sale, Shah directly holds 1,052,045 shares, and also reports indirect holdings of 207,897 shares held by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust.
Rocket Companies insider sale notice: a Form 144 lists 1,157 common shares related to restricted stock vesting dated 02/13/2026.
The filing also records prior sales by John Militello: 1,086 shares on 11/18/2025 and 3,726 shares on 02/13/2026.
RCKT filing of a Form 144 reports proposed sale of 1,376 common shares tied to restricted stock vesting dated 02/13/2026. The filing also records prior sales by the reporting person: 1,646 shares on 11/18/2025 and 12,253 shares on 02/13/2026.
Issuer reported Form 144 sale notice for restricted shares by an affiliate. The filing lists 5,990 common shares offered for sale related to a restricted stock vesting event on 02/13/2026. It also shows prior transactions by Gaurav Shah: 6,276 shares sold on 11/18/2025 and 12,279 shares sold on 02/13/2026.
Rocket Pharmaceuticals insider Martin Wilson has filed a notice to sell 12,253 common shares. The shares were recently acquired through restricted stock vesting on 02/11/2026 as compensation from the issuer. The planned sale through Fidelity Brokerage Services LLC has an aggregate market value of $40,583.16 and is listed for trading on NASDAQ, with an approximate sale date of 02/13/2026. The filing notes that 108,222,228 common shares were outstanding, and also discloses a prior sale of 1,646 shares for $4,909.69 on 11/18/2025.
Maverick Capital and related entities filed an amended Schedule 13G reporting their beneficial ownership of Rocket Pharmaceuticals common stock. They report beneficial ownership of 2,513,110 shares of Rocket, representing 2.3% of the outstanding common stock, based on 108,222,228 shares outstanding as of October 31, 2025.
The shares are held for Maverick’s investment advisory clients, including Maverick HP, L.P. with 1,917,698 shares and certain separately managed accounts with 595,412 shares. The filers certify that the securities were not acquired to change or influence control of Rocket Pharmaceuticals.
Shah Gaurav reported acquisition or exercise transactions in a Form 4 filing for RCKT. The filing lists transactions totaling 1,156,676 shares. Following the reported transactions, holdings were 870,648 shares.